Skip to main content
Premium Trial:

Request an Annual Quote

Exact Sciences to Use MDxHealth Methylation Biomarker, PCR Tech in Cologuard Test

Premium

MDxHealth said this week that Exact Sciences will use MDxHealth's methylation biomarker and methylation-specific PCR technology in Cologuard, Exact's non-invasive, stool-based DNA colon cancer screening test currently under development.

Exact Sciences licensed several methylation biomarkers, among other biomarkers, and the PCR technology in July, before MDxHealth changed its name from OncoMethylome. Exact has been evaluating the technologies since that time, in studies with Cologuard.

The confirmation that Exact will use MDxHealth's technology triggers an undisclosed milestone payment to MDxHealth, which will also receive royalties on net sales once the test is commercialized.

Exact Sciences said that in a recently completed study involving samples from 1,100 patients, Cologuard was shown to detect 64 percent of colorectal pre-cancers and 85 percent of colorectal cancers. The company is now preparing to enroll several thousand patients in a prospective trial to obtain approval from the US Food and Drug Administration. It expects to complete the trial in 2012.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.